Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024.

Select Preliminary Financial Highlights

Fourth quarter 2024 total revenue is expected to be in the range of $18.9 million to $19.1 million, an increase of 1% at the estimated midpoint compared to the prior year period.

• Surgical Glaucoma revenues are expected to be in the range of $18.7 million to $18.8 million, an increase of 9% at the estimated midpoint compared to the prior year period.
• Dry Eye revenues are expected to be in the range of $0.2 million to $0.3 million, compared to $1.6 million in the prior year period.

Full year 2024 total revenue is expected to be in the range of $79.7 million to $79.9 million, a decrease of 2% at the estimated midpoint compared to the prior year.

• Surgical Glaucoma revenues are expected to be in the range of $75.8 million to $75.9 million, an increase of 2% at the estimated midpoint compared to the prior year.
  
   
• Dry Eye revenues are expected to be in the range of $3.9 million to $4.0 million, compared to $6.7 million in 2023.
  
   

The Company's cash and cash equivalents as of December 31, 2024, were approximately $120 million, compared to $118.6 million as of September 30, 2024.

• Cash generated in the quarter totaled approximately $1.4 million, reflecting continued operational discipline versus cash used in the same period of the prior year of $6.4 million.
• Cash generated in the quarter included a $5.0 million drawdown under our term loan with Hercules Capital, Inc. and certain affiliates of Hercules.
• Cash used during the year totaled approximately $18.1 million, down from $46.9 million cash used in the prior year.
• The Company plans to achieve cash flow breakeven without the need to raise additional equity capital.